Tumor markers, such as carbohydrate antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA), provide clinicians with information about cancer therapeutic response in advanced cancer stage and lack of practical information in early-stage breast cancer [7–9]. This evidence concerns the gene CEACAM5 and neoplasm.